Lassa vaccine
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique
InventorsMathieu MATEO, Sylvain BAIZE, Frédéric TANGY
Life of this patent
Estimating the term…
Abstract
The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.
Claims30
A nucleic acid construct which comprises:
- (1) a cDNA molecule encoding a full length antigenomic (+) RNA strand of a measles virus (MeV);
- (2) a first heterologous polynucleotide encoding at least one polypeptide, or an antigenic fragment thereof, of a Lassa virus (LASV), said at least one polypeptide being selected from the group consisting of the nucleoprotein (NP), a mutated nucleoprotein (mNP), the glycoprotein precursor (GPC) and the zinc-binding protein (Z);
- and wherein the first heterologous polynucleotide is operatively cloned within an additional transcription unit (ATU) inserted within the cDNA of the antigenomic (+) RNA, in particular an ATU localized between the P gene and the M gene of the MeV, in particular the ATU2 inserted between the P gene and the M gene of the MeV.
Dependencies are inferred from the claim text.